Medigene's global research & collaboration agreement with biontech to extend beyond initially announced term

Planegg/martinsried, may 21, 2024. medigene ag (medigene or the “company”, fse: mdg1, prime standard), an immuno-oncology platform company focusing on the discovery and development of differentiated t cell immunotherapies for solid tumors and biontech se (nasdaq: bntx, “biontech”) have announced that their collaboration to advance t cell receptor (tcr) immunotherapies against cancer will extend beyond the initial three-year term outlined at the signing of the agreement in february 2022. this extension will enable ongoing and future work required to potentially generate novel tcrs directed against multiple newly nominated antigen targets that could further expand the biontech warehouse of tcr candidates.
BNTX Ratings Summary
BNTX Quant Ranking